Compare
Atea Pharmaceuticals, Inc. vs LB Pharmaceuticals Inc vs ADC Therapeutics SA vs Sionna Therapeutics, Inc.
| Latest fiscal year | Atea Pharmaceuticals, Inc. AVIR | LB Pharmaceuticals Inc LBRX | ADC Therapeutics SA ADCT | Sionna Therapeutics, Inc. SION |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $81.36M | n/a |
| Revenue growth (YoY) | n/a | n/a | +14.9% | n/a |
| Gross margin | n/a | n/a | 92.9% (computed) | n/a |
| Operating margin | n/a | n/a | -149.3% | n/a |
| Net margin | n/a | n/a | -175.3% | n/a |
| Net income | -$158.35M | -$25.20M | -$142.62M | -$75.27M |
| EPS (Diluted) | -$1.94 | -$3.13 | -$1.12 | -$1.88 |
| Operating cash flow | -$132.03M | -$35.21M | -$141.17M | -$66.30M |
| Free cash flow | n/a | -$35.26M | -$141.44M | -$66.67M |
| Cash & equivalents | $95.71M | $250.17M | $261.34M | $58.45M |
| Total assets | $315.22M | $312.93M | $323.15M | $325.95M |
| Total liabilities | $39.78M | $11.62M | $508.98M | $19.12M |
| Shareholders' equity | $275.43M | $301.31M | -$185.83M | $306.83M |
| Return on year-end equity | -57.5% | -8.4% | n/a | -24.5% |
| Shares outstanding | 78.13M | 25.30M | 125.75M | 44.72M |
Revenue, most recent five fiscal years
| Fiscal year | Atea Pharmaceuticals, Inc. | LB Pharmaceuticals Inc | ADC Therapeutics SA | Sionna Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $351.37M Ended 2021-12-31 | n/a | $81.36M Ended 2025-12-31 | n/a |
| 1 year earlier | $48.63M Ended 2020-12-31 | n/a | $70.84M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $69.56M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $209.91M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |